There is little data describing trends in the use of hydroxychloroquine for COVID-19 following publication of randomized trials that failed to demonstrate a benefit of this therapy. We identified 13,957 patients admitted for active COVID-19 at 85 U.S. hospitals participating in a national registry between March 1 and August 31, 2020. The overall proportion of patients receiving hydroxychloroquine peaked at 55.2% in March and April and decreased to 4.8% in May and June and 0.8% in July and August. At the hospital-level, median use was 59.4% in March and April (IQR 48.5–71.5%, range 0–100%) and decreased to 0.3% (IQR 0–5.4%, range 0–100%) by May and June and 0% (IQR 0–1.3%, range 0–36.4%) by July and August. The rate and hospital-level uniformity in deimplementation of this ineffective therapy for COVID-19 reflects a rapid response to evolving clinical information and further study may offer strategies to inform deimplementation of ineffective clinical care.
【저자키워드】 viral infection, Psychology and behaviour, 【초록키워드】 COVID-19, therapy, Hydroxychloroquine, hospital, randomized trial, Patient, clinical care, rapid response, clinical information, National, offer, benefit, proportion, peaked, receiving, median, reflect, IQR, therapy for COVID-19, use of hydroxychloroquine, 【제목키워드】 COVID-19, Hydroxychloroquine, registry, CVD, cross-sectional analysis, AHA,